1588442-07-2

Upstream product

• 1588441-93-3 tert-butyl N4-(2′-bromophenyl)-5-bromocytosin-1-ylacetate 
• 476667-21-7 (5-bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)acetic acid tert-butyl ester 
• 476667-22-8 tert-butyl 4-(1′,2′,4′-triazol-1′-yl)-5-bromocytosin-1-ylacetate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1588442-06-1 C₂₈H₃₁Br₂N₅O₆ 

Downstream Products

• 1588442-08-3 C₂₈H₃₁N₅O₆ 

Relevant academic research and scientific papers

Pyrimidine-fused heterocyclic frameworks based on an N4-arylcytosine scaffold: Synthesis, characterization, and PNA oligomerization of the fluorescent cytosine analogue 5,6-benzopC

A synthesis of an intrinsically fluorescent cytosine analogue 5,6-benzopC has been developed utilizing the reductive Ni-mediated cyclization of an N4-aryl,N4-(Boc)cytosine intermediate as a key step. 5,6-BenzopC was found to possess interesting fluorescence properties (φ = 0.79, EtOH; Stokes shift 113 nm). Peptide nucleic acid (PNA) oligomerization of the 5,6-benzopC monomer was carried out, followed by hybridization studies with complementary deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) which showed the modification to be well tolerated in the sequence contexts examined. Initial attempts to synthesize the heterocyclic skeleton present in 5,6-benzopC resulted in the discovery of routes to the pyrimido[1,6-a]benzimidazole, pyrimido[1,6-a]quinazoline, and pyrimido[1,6-a]benzo[b]6-bora-1,3-diazine heterocyclic frameworks.